ArticleNature communications2026
Novel surveillance design exploiting network analysis for efficient, rapid detection of emerging Clostridioides difficile strains.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Whole genome sequencing is being introduced in England to support national surveillance of key hospital-acquired pathogens, starting with Clostridioides difficile, to facilitate novel strain identification and enable timely interventions. However sequencing capacity is limited. Symptomatic and asymptomatic patients attending multiple hospitals can act as inter-facility transmission vectors; here we therefore identify the empirical network of shared patients from analysing national admission data and simulate spread of a hypothetical novel strain. Algorithmically optimising detection, incorporating logistical constraints, we identify sentinel sites which detect a novel strain 27% faster than random sentinel selection, whilst sequencing <15% cases. Sensitivity and scenario analyses using a range of plausible pathogen characteristics and historical networks confirm epidemiologically- and longitudinally-robust sentinel selection and performance. The new surveillance system, established from our findings, benefits from stress-tested sentinel set selection to deliver rapid, efficient identification of novel strains within real world constraints, to inform control interventions, and provides a roadmap for future hospital-acquired pathogen surveillance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.